Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Press Releases

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida.

A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Therapeutics Contact:

investors@aclaristx.com 

Related Articles
TheFlyAclaris announces first patient dosed in Phase 2a trial of ATI-2138
TheFlyAclaris Therapeutics expects cash to fund operations into 2028
TheFlyAclaris Therapeutics reports Q2 EPS (15c), consensus (20c)
Go Ad-Free with Our App